About: LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Sector: Healthcare
Industry: Biotechnology
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
LVTX NASDAQ LAVA Therapeutics NV
LAVA Therapeutics NV share price
Atividade de preço de LVTX
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
LVTX price performance
quote.marketSignals